HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Alenza, D. P. Articles by Melian, C. Search for Related Content PubMed PubMed Citation Articles by Alenza, D. P. Articles by Melian, C.

Long-Term Efficacy of Trilostane Administered Twice Daily in Dogs With Pituitary-Dependent Hyperadrenocorticism

From the Veterinary Teaching Hospital (Perez Alenza, Arenas), Veterinary School, Complutense University of Madrid, 28040 Madrid, Spain and Clinica Veterinaria Atlantico (Lopez, Melian), Pi y Margall, 42, 35006, Las Palmas de Gran Canaria, Spain.

Address all correspondence to Dr. Arenas.

Trilostane is considered an efficacious and safe medication for canine pituitary-dependent hyperadrenocorticism (PDH). Its recommended frequency of administration is once daily. In this prospective study, the efficacy, toxicity, and long-term outcome of trilostane administered twice daily per os were evaluated in 44 dogs with PDH. Mean initial dose was 3.1 mg/kg q 12 hours, and mean final dose was 3.2 mg/kg q 12 hours. The final total daily dose was lower than previously reported for once-daily administration. The mean survival time for affected dogs was 930 days.

This article has been cited by other articles:

				M. Clemente, P. J. De Andres, C. Arenas, C. Melian, M. Morales, and M. D. Perez-Alenza Comparison of non-selective adrenocorticolysis with mitotane or trilostane for the treatment of dogs with pituitary-dependent hyperadrenocorticism Vet Rec., December 15, 2007; 161(24): 805 - 809. [Abstract] [Full Text] [PDF]